Exhibitor List
PreludeDx
Booth 337
PreludeDx provides a patented molecular test (DCISionRT®) for women diagnosed with DCIS (Ductal Carcinoma in Situ) that predicts a woman’s personal likelihood or risk of developing DCIS recurrence in 10 years and invasive breast cancer in 10 years with or without adjuvant radiation therapy after breast conserving surgery. Visit PreludeDx.com.